** GENERIC SPECIALS - DEEP DISCOUNTS **

"Generics Campaign"

NEW CAMPAIGN DATES 2/29/20 – 3/28/20

ADDITIONS:

REMOVALS:

Current Discounted Item Price list:

Regular ordering through McKesson - discount PERCENTAGE
will be in place during campaign period.

Click here to check out a full list of Custom Discounted Items on our website weekly - updated every Monday! (site login required)

Prices below are as of 2/24/2020 and are subject to change with or without notice:

FORMULARY CHANGES:

We have received request from many of you asking how to determine when changes to the formulary items on our One Stop program will occur. There is a list available on the OneStop Generics homepage. Click on this link to go to the homepage and select the list to review under the Formulary Changes banner.

REASONS FOR CHANGES TO FORMULARY:

• Formulation Change: A manufacturer may change product formulation, for example, in response to user preference.
• Supply Discontinuation: A manufacturer may discontinue supplying a product.
• Supply Issues: A manufacturer change may be initiated to insure more reliable supply and higher customer service levels
• Price: If market prices begin to change McKesson Sourcing Team will seek other suppliers to provide better pricing to our members.

FDA GENERIC NEWS:

FDA approves first generic of ProAir HFA (albuterol sulfate) inhalation aerosol

The U.S. Food and Drug Administration approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.

The most common side effects associated with Albuterol Sulfate Inhalation Aerosol are headache, rapid heart rate (tachycardia), pain, dizziness, sore throat (pharyngitis), rhinitis, chest pain, palpitations, tremor and nervousness.

FDA Drug Competition Action Plan

Helps remove barriers to generic drug development and market entry so that consumers can get access to needed medicines

Bringing more drug competition to the market and addressing the high cost of medicines is a top priority of the Administration, the Department of Health and Human Services (HHS), and FDA. In 2017, FDA announced the Drug Competition Action Plan (DCAP) to further encourage robust and timely market competition for generic drugs and help bring greater efficiency and transparency to the generic drug review process, without sacrificing the scientific rigor underlying our generic drug program. Through this plan, FDA is helping remove barriers to generic drug development and market entry in an effort to spur competition so that consumers can get access to the medicines they need at affordable prices.

To date, the Agency has focused its efforts under the Drug Competition Action Plan in three key areas: 

1. improving the efficiency of the generic drug development, review, and approval process; 
2. maximizing scientific and regulatory clarity with respect to complex generic drugs; and 
3. closing loopholes that allow brand-name drug companies to “game” FDA rules in ways that delay the generic competition Congress intended. 

Actions intended to improve the efficiency of the generic drug development, review, and approval process:

The following initiatives help bring greater transparency to the generic drug review and approval process, with the ultimate goal of more approvals. By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval. At the same time, FDA is implementing initiatives to enhance its own review process efficiency to improve the speed and predictability of the generic drug review process while maintaining our rigorous scientific standards.

Action Plan

• List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic (Updated December 2019, June 2019, December 2018, June 2018, December 2017; originally published June 2017)
• Draft Guidance for Industry “Transdermal and Topical Delivery Systems – Product Development and Quality Considerations” (November 2019)
• Draft Guidance for Industry: Harmonizing Compendial Standards with Drug Application Approval Using the USP Pending Monograph Process (July 2019)
• Draft Guidance for Industry: Using the Inactive Ingredient Database (July 2019)
• Updates to FDA’s website on Patent Certifications and Suitability Petitions (June 2019)
• Final Guidance for Industry: Determining Whether to Submit an ANDA or a 505(b)(2) Application (May 2019)
• Draft Guidance for Industry: Competitive Generic Therapies (February 2019)
• Draft Guidance for Industry: CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality (February 2019)
• Draft Guidance for Industry: ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs (January 2019)
• Final Guidance for Industry: Amendments to Abbreviated New Drug Applications Under GDUFA (July 2018)
• Draft Guidance for Industry: Good ANDA Submission Practices (January 2018)
• MAPP: Good ANDA Assessment Practices (January 2018)
• Addition of patent submission dates to Approved Drug Products with Therapeutic Equivalence Evaluations – known as the “Orange Book” – where available (November 2017)
• Revisions to the Prioritization of the Review of Original ANDAs, Amendments, and Supplements MAPP (November 2017, June 2017)
• Draft Guidance for Industry: ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) (November 2017)
• Updated Practice – FDA will issue product-specific or product-class specific guidance on how generic copies of newly approved, non-complex new chemical entity drugs can be developed, and make such guidance available at least two years prior to the first lawful ANDA submission date. (October 2017)

APCI Vendor Offerings

Ananda Professional

Sure Comfort

Centor

Vet4U Rx